Navigation Links
BioMarin Announces First Quarter 2011 Financial Results
Date:4/28/2011

candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... DIEGO, Nov. 8, 2010 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... three and nine months ended September 30, 2010. ... prudent cash management and reflected $29.3 million in cash at ... ADVENTRX.  "We recently submitted a New Drug Application to the ...
... 2010 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... and biotechnology research and development outsourcing company, today announced ... the Company,s Board of Directors and Audit Committee, effective ... Officer and Chief Operating Officer of ShangPharma, will resign ...
Cached Medicine Technology:ADVENTRX Reports Third Quarter Financial Results 2ADVENTRX Reports Third Quarter Financial Results 3ADVENTRX Reports Third Quarter Financial Results 4ADVENTRX Reports Third Quarter Financial Results 5ADVENTRX Reports Third Quarter Financial Results 6ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee 2
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
Breaking Medicine News(10 mins):Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... Sports as a,distributor of Muscle Pharm products throughout the US. ... and online,fulfillment. , "Having ... help service many,of our customers who call on a daily ... , For inquires about ...
... President of Preclinical Sciences and Marie Green, Ph.D., as ... CAMBRIDGE, Mass., Dec. 1 Taligen Therapeutics ... the appointment of Jeffrey T. Walsh as chief business ... Christopher Horvath, D.V.M., as vice president of preclinical sciences ...
... Computer Services,Inc. (NYSE: ACS ) re-enters the ... government agencies lower costs and increase service.,With the expiration ... a few,agencies, ACS can now offer its proven business ... As the U.S. faces ...
... generations often shared,wonderful memories of active and healthy grandparents ... years. In the last century, with,life expectancy having ... ages",are much more encumbered by health care concerns, which ... care for themselves. In the recently published,Evercare(R) Study of ...
... include information on the story of one soldier,s family who have ... wound of soldiers returning from Iraq is a traumatic brain injury, ... , ... Denver, CO (PRWEB) December 1, 2008 -- ...
... employers and recruiters to use just one source for all ... jobs posted by different employers across the country. Healthcare employers ... The Exchange simplifies and expedites the hiring process for the ... ...
Cached Medicine News:Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 2Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 3Health News:Take Time to Care for the Caregiver 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 3Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 2Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 3
... Featuring an expanded database containing over ... identification cards, VITEK 2 Compact offers ... amount of time (2 to 14 ... of microorganisms that contaminate production areas ...
... transmitting data from multiple sources is ... Dawnings ResultNet/Plus software allows you to ... your communications network., ,ResultNet/Plus eliminates the ... from largescale or multi-site laboratories to ...
... Software is a powerful Java-based interface ... to control laboratory instrument connections and ... used in two applications: embedded in ... on a network PC station. Within ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
Medicine Products: